April 24, 2023
Fascinating presentation by our R&D Director Lyora Aharonov at the Weizman Institute of Science! Great job👏 Read More >>>
NurExone’s research and development investment grew by 143.9% from US$0.57 million in 2021 to US$1.39 million in 2022, due to increased activity in preclinical trials in the Company’s labs. The Company recently disclosed additional results from an internal preclinical study of its investigational drug, ExoPTEN, which demonstrated effective treatment of 75%
Amazing #volunteerwork of NurExone Biologic’s team members as part of the global Good Deeds Day! 👏 👏 👏 Our team members Lior Shaltiel, PhD, Lyora Aharonov, Kineret Taler, Lulu Fahoum and Saray Tabak, Ph.D was assigned to the Israeli association “giving with love” (Notnim Bea’ava, Haifa), who distribute food packages
The Company’s most recent preclinical trials, that have taken place over 10 weeks in NurExone’s labs in Israel, have proven that its experimental drug ExoPTEN caused 75% of rat subjects in the study to regain hind limb reflex, some motor function, and sensory control. These rats, who regained function, also